4-[3-(2-Chlorophenyl)pyrrolo[3,2-c]pyridin-1-yl]pyrimidin-2-amine | 1428226-74-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-[3-(2-Chlorophenyl)pyrrolo[3,2-c]pyridin-1-yl]pyrimidin-2-amine
• 英文别名: 4-[3-(2-chlorophenyl)pyrrolo[3,2-c]pyridin-1-yl]pyrimidin-2-amine
• CAS: 1428226-74-7
• 化学式: C₁₇H₁₂ClN₅
• 分子量: 321.769
• InChiKey: DGPFURGWWCIZHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-氮杂吲哚 在 四(三苯基膦)钯 、 碘 、 potassium carbonate 、 potassium hydroxide 作用下， 以 乙醇 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 生成 4-[3-(2-Chlorophenyl)pyrrolo[3,2-c]pyridin-1-yl]pyrimidin-2-amine
  参考文献：
  名称：

  N-substituted azaindoles as potent inhibitors of Cdc7 kinase

  摘要：

  Cdc7 kinase is responsible for the initiation and regulation of DNA replication and has been proposed as a target for cancer therapy. We have identified a class of Cdc7 inhibitors based on a substituted indole core. Synthesis of focused indole and azaindole analogs yielded potent and selective 5-azaindole Cdc7 inhibitors with improved intrinsic metabolic stability (ie 36). In parallel, quantum mechanical conformational analysis helped to rationalize SAR observations, led to a proposal of the preferred binding conformation in the absence of co-crystallography data, and allowed the design of 7-azaindole 37 as a second lead in this series. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.007

文献信息

• N-substituted azaindoles as potent inhibitors of Cdc7 kinase
  作者：Marian C. Bryan、James R. Falsey、Mike Frohn、Andreas Reichelt、Guomin Yao、Michael D. Bartberger、Julie M. Bailis、Leeanne Zalameda、Tisha San Miguel、Elizabeth M. Doherty、John G. Allen

  DOI：10.1016/j.bmcl.2013.02.007

  日期：2013.4

  Cdc7 kinase is responsible for the initiation and regulation of DNA replication and has been proposed as a target for cancer therapy. We have identified a class of Cdc7 inhibitors based on a substituted indole core. Synthesis of focused indole and azaindole analogs yielded potent and selective 5-azaindole Cdc7 inhibitors with improved intrinsic metabolic stability (ie 36). In parallel, quantum mechanical conformational analysis helped to rationalize SAR observations, led to a proposal of the preferred binding conformation in the absence of co-crystallography data, and allowed the design of 7-azaindole 37 as a second lead in this series. (C) 2013 Elsevier Ltd. All rights reserved.